Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pu-Hyeon Cha
A Small Molecule Approach to Degrade RAS With EGFR Repression Is a Potential Therapy for KRAS Mutation-Driven Colorectal Cancer Resistance to Cetuximab
Experimental and Molecular Medicine
Biochemistry
Medicine
Clinical Biochemistry
Molecular Biology
Molecular Medicine
Related publications
Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer
Nature
Multidisciplinary
Mechanism of Resistance to Cetuximab Therapy in Colorectal Cancer
mAbs
Allergy
Immunology
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
Cancers
Cancer Research
Oncology
GC1118, a Novel Anti-Egfr Antibody, Has Potent KRAS Mutation-Independent Antitumor Activity Compared With Cetuximab in Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan
JAMA Oncology
Cancer Research
Oncology
Nuclear EGFR Contributes to Acquired Resistance to Cetuximab
Oncogene
Cancer Research
Genetics
Molecular Biology
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
Cancer Cell
Cancer Research
Oncology
Cell Biology
EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment
JCO Precision Oncology
Cancer Research
Oncology
Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
